Imaging Neuroinflammation In COVID-19 and Persistent Depression With/Without Other Neuropsychiatric Symptoms
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:3 publications
Grant number: 174893
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$601,328.25Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
Jeffrey H MeyerResearch Location
CanadaLead Research Institution
Centre for Addiction and Mental Health/Centre de toxicomanie et de santé mentaleResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Disease pathogenesis
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
COVID-19 is infecting 1 in 100 Canadians and over 23 million people around the world. After people recover from short term breathing problems, and feelings of sickness with the virus, there can be longer term problems affecting the brain. It is believed that the virus can cause inflammation of the brain. We know that inflammation in the brain is implicated in causing depression symptoms. About 30% of those infected with COVID-19 report later elevations in level of depression and/or other symptoms of mental illness. The purpose of this study is to use state of the art brain scanning to detect whether brain inflammation is happening in those with COVID-19 who later get depression and/or other mental illnesses. There are two main purposes for this study. First, it would be the first to show definitive evidence of brain inflammation in COVID-19 with later mental illness. Second, if we discover brain inflammation, we can study treatments to see if they can prevent or remove this inflammation, using the brain scan to show that the treatment has an effect in the brain. Having a brain scan to detect COVID-19 effect in the brain is extremely important for developing new brain treatments for COVID-19: Most companies and many government funding agencies like the National Institutes of Health in the US, require use of brain scanning to show that brain treatments get into the brain as a requirement to invest funds for clinical trials.
Publicationslinked via Europe PMC
Last Updated:an hour ago
View all publications at Europe PMC